Artificial intelligence

Sanofi anticipates study results for an arthritis drug repurposed to treat COVID-19 will be availabe imminently, which along with Regeneron is testing the immune-blocking therapy Kevzara in two clinical trials.
By 2030 there will be a 100 per cent rise in the number of people with arthritis to 17 million.
An occurrence of chronic disorders such as cancer, anemia, diabetes, autoimmune diseases, kidney failure, rheumatoid arthritis, infectious diseases and deficiency of growth hormones is projected to fuel the global biosimilars industry in the coming years.
The United Kingdom alone expects a 29% rise in the incidence of diabetes by 2025, as well as a doubling of the incidence of arthritis by 2030.
Cosentyx is expected to be Novartis' top-selling drug during 2019, with robust growth in all three approved indications: plaque psoriasis, psoriatic arthritis, and ankylosing spondylitis.
The report confirms poor-quality housing now costs the NHS a staggering £1.4bn every year with cold, damp, and other hazards causing falls and exacerbating conditions such as heart disease, strokes, respiratory illnesses, and arthritis, as well as contributing to poor mental health.
After further research in mice and, eventually, humans, intestinal microbiota and metabolic signatures could help scientists build a predictive profile for who is likely to develop rheumatoid arthritis and the course the disease will take.
By 2030, total knee replacement is projected to grow by up to 189%, according to the American Academy of Orthopaedic Surgeons, and 90% of people who receive one report less pain from chronic conditions such as arthritis.
The substantial cost of hip implant surgeries is one of the major factors expected to hamper the growth of the global market.
Otezla is Celgene's marketed oral drug for psoriasis and psoriatic arthritis that had sales of $1.6 billion in 2018, and that number is rising to $2.5 billion in 2023.
The rheumatoid arthritis and psoriasis markets are largely mature, but could see around $5 billion to $10 billion in expansion.
According to the Centers for Disease Control and Prevention (CDC), around 78 million (26%) US adults aged 18 years or older are projected to have doctor-diagnosed arthritis by 2040.
According to the projections by the CDC, an estimated 78 million people in the U.S. are going to be affected by some form of arthritis by the year 2040.
According to the Centers for Disease Control and Preventions (CDC), 25.9% of the adult population in the US will be diagnosed with Arthritis by 2040.
According to Centers for Disease Prevention and Control (CDC), an estimate of 78.4 million adults aged 18 years or above will have doctor-diagnosed arthritis by 2040 in the U.S., as compared to 54.4 million adults in 2013 to 2015.
In the United States, 54 million adults have some form of doctor-diagnosed arthritis , a number projected to increase to 78 million by 2040.
The world health organization predicts the prevalence of Rheumatoid Arthritis to be between 0.3% and 1% and more common in women and in developed countries.
The demand for wheelchairs from the geriatric population will extensively increase in the coming years: Market research analysts predict that this global market will register a revenue of more than USD5.4 billion by 2022.
By 2030 there will be 17 million people in the UK with arthritis and 3 million with cancer.
Global chronic pain treatment market is expected to witness considerable growth due to current unmet medical need of chronic pain.
A class of anti-inflammatory drugs already FDA-approved for rheumatoid arthritis could "purge" the reservoir of infected immune cells in people infected by HIV.
Middle East & Africa will grow at moderate rate in rheumatoid arthritis treatment market owing to factor the treatment cost is high for the disease.

See full forecast

Last updated: 20 September 2020